GP 1683

Drug Profile

GP 1683

Alternative Names: GP 683

Latest Information Update: 16 Dec 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SICOR
  • Developer Metabasis Therapeutics; SICOR
  • Class Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action Adenosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Seizures; Stroke

Most Recent Events

  • 16 Dec 1998 Discontinued-Preclinical for Seizures in USA (Unknown route)
  • 16 Dec 1998 Discontinued-Preclinical for Stroke in USA (Unknown route)
  • 27 Oct 1998 A study has been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top